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ABSTRACT
Background and aim Acute pancreatitis
(AP) is associated with organ failures and
systemic complications, most commonly acute
respiratory failure (ARF) and acute kidney
injury. So far, no studies have analysed the
predictors and hospitalisation outcomes, of
patients with AP who developed ARF. The aim
of this study was to measure the prevalence
of ARF in AP and to determine the clinical
predictors for ARF and mortality in AP.
Methods This is a retrospective cohort study
using the Nationwide Inpatient Sample
database from the year 2005–2014. The study
population consisted of all hospitalisations
with a primary or secondary discharge
diagnosis of AP, which is further stratified
based on the presence of ARF. The outcome
measures include in-hospital mortality, hospital
length of stay and hospitalisation cost.
Results In our study, about 5.4% of patients
with AP had a codiagnosis of ARF, with a
mortality rate of 26.5%. The significant
predictors for ARF include sepsis, pleural
effusion, pneumonia and cardiogenic shock.
Key variables that were associated with a
higher risk of mortality include mechanical
ventilation, age more than 65 years, sepsis
and cancer (excluding pancreatic cancer).
The presence of ARF increased hospital stay
by 8.3 days and hospitalisation charges by
US$103 460.
Conclusion In this study, we demonstrate that
ARF is a significant risk factor for increased
hospital mortality, greater length of stay and
higher hospitalisation charges in patients
with AP. This underlines significantly higher
resource utilisation in patients with a dual
diagnosis of AP-ARF.

Significance of this study
What is already known on this topic

►► Acute pancreatitis is associated with

organ failures and systemic complications,
most commonly acute respiratory failure
and acute kidney injury. Population-based
data on the effect of acute respiratory
failure in acute pancreatitis are limited in
terms of predictors and outcomes.

What this study adds

►► We found that in a nationwide study,

5.4% of patients hospitalised with
acute pancreatitis had acute respiratory
failure, with a mortality rate of 26.5%.
The presence of acute respiratory failure
increased hospital stay by 8.3 days and
hospitalisation charges by US$103 460.
The significant predictors for acute
respiratory failure include sepsis, pleural
effusion, pneumonia and cardiogenic
shock. Key variables that were associated
with a higher risk of mortality include
mechanical ventilation, age more than
65 years, sepsis and cancer (excluding
pancreatic cancer).

How might it impact on clinical
practice in the foreseeable future

►► Concurrent acute respiratory failure

in hospitalised patients with acute
pancreatitis occurs at a perceptible
prevalence with noticeable complications.
This subgroup seems to have an overall
poor prognosis and a more protracted
clinical course compared with patients
with acute pancreatitis with other organ
failures. These results can be useful in
allocating healthcare resources and
counselling patients. Also, future scoring
systems should consider giving more
weightage for acute respiratory failure.
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INTRODUCTION
Acute pancreatitis (AP) is one of the most common
causes of gastrointestinal hospitalisation, with more
than 200 000 hospitalisations a year in the USA, with
an estimated expenditure of US$2.6 billion every year.1
The incidence of AP has been shown to be increasing
over the years, with a decrease in the mortality rates.2 3
Based on the 1992 Atlanta classification, AP was classified into mild AP and severe AP. The 2012 revised
Atlanta classification reclassified AP into mild acute,
moderately severe and severe AP. Mild AP is self-
limited without organ failure (OF) or complications;
moderately severe AP can present with transient OF or
complications that persist less than 48 hours and severe
AP manifest with persistent OF that persists more than
48 hours.4 5 Approximately 70%–80% of AP would
take a mild course, and 15%–25% would have a severe
course that usually occurs within the first 4 days.6 7
AP has been associated with OFs and systemic
complications, most commonly acute respiratory
failure (ARF), and acute kidney injury.8 Previous
studies have revealed AP as a significant risk factor
for ARF.9–12 Severe AP predisposes to ARF, and ARF,
in turn, adversely influences clinical outcome in
AP.11 12 Two principal forms of ARF are acute lung
injury (ALI) and acute respiratory distress syndrome
(ARDS), which are responsible for high mortality rates
in severe AP.13 ARDS is considered as the most severe
form of ALI, and they can be distinguished based on
arterial oxygen pressure and inspired oxygen concentration ratio (PaO2/FiO2).14 The overall mortality rate
due to ARDS and ALI is between 30% and 40% from
all causes.14 ARDS is characterised by diffuse alveolar
damage, lung capillary endothelial injury and diffuse
pulmonary oedema that impairs gas exchange.15
Population-based data on the effect of ARF in AP
are limited. Previous studies are derived from single-
tertiary care referral centres, which do not represent
the community setting of all patients with AP but
represent a ‘sicker’ group of patients.16 Lastly, no
studies have analysed the predictors and hospitalisation outcomes of patients with AP who developed
ARF. The aims of this study are: (1) to measure the
prevalence of ARF in AP (2) to determine the clinical
predictors for ARF in patients with AP (3) to determine the clinical predictors for in-hospital mortality in
patients with AP-ARF and (4) to measure the outcome
comparisons such as in-hospital mortality, length of
stay (LOS) and hospital charges for patients with and
without ARF. Currently, there are no studies that have
focused on these inquiries.
METHODS
This is a retrospective cohort study using the Nationwide Inpatient Sample (NIS) database from the year
2005 to 2014. The NIS database consists of a 20%
stratified sample of all discharges from the participating
hospitals with data on more than 8 million discharges

per year. Each discharge is treated as a unique entry
and is coded with one primary discharge diagnosis and
up to 25 secondary diagnoses as well as 15 associated
procedures coded using the International Classification
of Diseases, Clinical Modification, ninth edition (ICD-
9-CM Codes). The NIS is maintained as part of the
Healthcare Cost and Utilization Project of the Agency
for Healthcare Research and Quality (AHRQ).17
The study population consists of all hospitalisations of adult patients (>18 years) with a primary or
secondary discharge diagnosis of AP queried using
the ICD-9-CM code 577.0 which has been validated
in various studies18–21 (online supplementary table 1).
Patients with ARF were identified using ICD-9 CM
codes 518.5, 518.81 or 518.82, which has been validated in previous studies.22–28 Patients with chronic
pancreatitis, pancreatic cancer and missing mortality
data were excluded. Our primary population of
interest was patients with AP with ARF (AP-
ARF
group), whereas the patients with AP with no organ
failure (AP-
NOF) and patients with AP with other
organ failure (AP-OOF) formed the control groups.
AP-
OOF is defined by the presence of acute renal
failure or acute cardiac failure or both. The primary
outcome is hospital mortality, and the secondary
outcomes are hospital LOS and hospitalisation cost.
Subgroup analysis was performed for patients with
ARF as the primary diagnosis and in patients with
multiorgan failure (MOF, defined by >2 OF).
Patients with AP with OF were classified into isolated
ARF, renal failure, cardiovascular failure or MOF. We
could only determine whether the patient had any OF
or not, and how many OFs the patient had based on
the ICD coding. However, it is not possible to determine whether the OF is transient or persistent due to
the lack of this information in the dataset. This makes
it difficult for us to determine whether the patient
had moderately severe or severe AP. Comorbidity risk
adjustment was performed using the AHRQ comorbidity measures based on the methods by Elixhauser et
al.29 We could not assess Ranson’s criteria, Acute Physiology and Chronic Health Evaluation (APACHE)-II
or Bedside Index for Severity in Acute Pancreatitis
(BISAP) score due to the unavailability of the laboratory data. The information on race was missing in 14%
of the patients and was treated as a separate category.
Descriptive summary statistics are presented as
means with SD for continuous variables, and frequencies with percentages for categorical variables. Categorical and continuous variables were compared using
χ2 tests and t-tests, respectively. Multivariable logistic
regression analysis was used to predict the risk factors
for ARF and mortality. The clinically relevant variables
with p<0.05 from univariate analysis were included in
the multivariable analysis. The results in the regression
models were represented by an OR and 95% CI. Data
analysis was performed using IBM SPSS software V.24
(SPSS).
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Figure 1

Study flow chart. NIS, Nationwide Inpatient Sample.

RESULTS
From 2005 to 2014, there were 750 531 hospitalisations for AP and 40 594 hospitalisations for AP-ARF
(figure 1). The prevalence of ARF in AP was 5.4% in
our study population, with a mortality rate of 26.5%.
From 2005 to 2014, the prevalence of both AP hospitalisations and AP-ARF has increased, with a decrease
in the mortality rates (figure 2, online supplementary table 2). The demographic characteristics of the
AP-ARF group, compared with two control groups,
AP-NOF and AP-OOF, have been outlined in table 1.
One of the most striking findings of this study is the
higher prevalence of sepsis in the AP-ARF group when
compared with AP-
OOF and AP-
NOF (50.7% vs
16.6% vs 3.2%, p<0.001). A significant proportion
of patients with AP-ARF also had coexisting OFs, with
12.6% of patients having isolated OF and 4.2% of the
patients having MOF (table 2). Among the patients
with isolated OF, the most common was an acute renal
failure (9%) followed by ARF (2.1%) and acute cardiac
failure (1.5%).
The in-hospital mortality occurred in 26.5%, 5.3%
and 0.5% of AP-ARF, AP-OOF and AP-NOF, respectively. The mean LOS for patients in AP-
ARF was
significantly higher than the patients in the control
groups, AP-
OOF and AP-
NOF (19.2 days vs 8.8
days vs 4.9 days p<0.001). After adjusting for age,
gender, hospital characteristics, AP aetiology comorbidity burden and hospital complications, AP-
ARF
groups had an adjusted LOS increased by 8.3 days
as opposed to those without ARF (8.3 days, 95% CI
8.2 to 8.4, p<0.001). Similarly, the hospital charges
were significantly higher in the AP-ARF group when
compared with the control groups, AP-
OOF and
AP-NOF (US$197 077 vs US$66 741 vs US$31 605,
p<0.001). After adjusting with the above-mentioned
variables, ARF in AP was associated with an additional
cost of nearly US$100 000 (103 460; 95% CI 103 085
to 103 836, p<0.001).
480

Predictors of ARF in AP and predictors of mortality
in AP-ARF are outlined in tables 3 and 4, respectively.
Sepsis is the strongest predictor for developing ARF
(OR 15, 95% CI 14.7 to 15.4), followed by pleural
effusion (OR 4, 95% CI 3.9 to 4.2), pneumonia (OR
3.8, 95% CI 3.5 to 4.2), cardiogenic shock (OR 3.2,
95% CI 3.1 to 3.4) and alcohol aetiology (OR 2.3,
95% CI 2.2 to 2.4). The most important predictors of
mortality in AP-ARF were mechanical ventilation (OR
14.2, 95% CI 13.6 to 14.8), age >65 (OR 5.0, 95% CI
4.6 to 5.4), sepsis (OR 5.1, 95% CI 4.9 to 5.3), cancer
(OR 2.8, 95% CI 2.6 to 2.9), cardiogenic shock (OR
2.5, 95% CI 2.3 to 2.6) and alcohol aetiology (OR
2.2, 95% CI 2.1 to 2.4). The patients with pancreatic
pseudocyst, smoking, obesity and diabetes mellitus had
a lower risk of mortality in AP-ARF.
About 0.3% of the study population patients were
admitted with a primary diagnosis of ARF (online
supplementary table 3). This subgroup had ARDS in
72.8% of the patients, which is much higher than the
rate of ARDS in the overall group (55.5%) and had
sepsis in 26% of the patients, which is much lower
than the overall sepsis rate of 50.7% in the AP-ARF
group. Also, they had a mortality rate of 24.2%,
which is lower than the overall mortality rate of 26.5
in the AP-ARF group. Patients with MOF had higher
mortality rates than those with one OF or no OF (28%
vs 6.5% vs 0.4%, p<0.001).
DISCUSSION
In this study, we demonstrate that about 5% of all
hospitalisations for AP were complicated by ARF.
We identified that ARF is a significant risk factor for
increased hospital mortality, LOS, mechanical ventilation and hospitalisation charges in patients with AP.
This subgroup of patients with AP with ARF seems to
have an overall poor prognosis when compared with
the patients with other OFs and those without any OF.
This study also confirms the increasing annual prevalence of total AP hospitalisations as well as the AP-ARF
hospitalisations.
In our study, the hospitalisation rates of ARF in
AP increased by 1% over the 10-
year period, and

Figure 2 Trends in acute respiratory failure (ARF) and acute
pancreatitis (AP). Red: AP mortality; blue: AP-ARF incidence; green:
AP-ARF mortality.
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Table 1

Demographic of the patients with acute pancreatitis
AP-NOF

AP-ARF

AP-OOF

N

n=624 617

n= 40594

n=85 320

Factor

N (%)

N (%)

N (%)

P value

Age (years), mean (SD)
Length of stay, mean (SD)
Total charges, mean (SD)
Gender: female*
Age cat
 18–35
 36–50
 51–65
 >65
Weekend admission
Race
 White
 Black
 Hispanic
 Asian or pacific islander
 Native American
 Other
 Missing
Hospital bed size*
 Small (1–49)
 Moderate (50–99)
 Large (>100)
Teaching status
 Rural
 Urban, non-teaching
 Urban, teaching
Payer*
 Medicare
 Medicaid
 Private
 Uninsured/other
Disposition
 Routine
 Short-term hospital
 Facility (SNF, ICF)
 Home healthcare
 Against medical advice
 Died
 Other
AHRQ—Elixhauser Comorbidity Index: >3††
Pancreatitis aetiology
 Alcohol
 Biliary
 Both alcohol and biliary
 Missing/unknown
Pancreatic pseudocyst
Pneumonia
Pleural effusion
Acute respiratory distress syndrome

52.82 (18.14)
4.95 (5.31)
31 605.1 (43 509.2)
323 511 (51.8%)
 
120 593 (19.3)
173 660 (27.8)
169 689 (27.2)
160 675 (25.7)
159 563 (25.5)
 
346 222 (55.4)†
78 128 (12.5)
76 133 (12.2)
11 820 (1.9)
4623 (0.7)
16 299 (2.6)
91 392 (2.6)
 
98 735 (15.9)
167 098 (26.9)
356 051 (57.3)
 
93 636 (15)
281 246(45)
247 002 (39.5)
 
203 981 (32.7)
97 325 (15.6)
211 485 (33.9)
110 202 (17.7)
 
516 750 (82.7)
17 030 (2.7)
36 275 (5.8)
33 121 (5.3)
17 966 (2.9)
3326 (0.5)
149 (0)
237 992 (38.1)
 
122 972 (19.7)
169 801 (27.2)
10 240 (1.6)†
321 603 (51.5)
23 077 (3.7)
1844 (0.3)
14 609 (2.3)
0 (0)

59.45 (17.22)
19.25 (20.06)
197 077.1 (238 188.2)
17 561 (43.2)
 
4066 (10)
8327 (20.5)
12 423 (30.6)†
15 778 (38.9)
10 593 (26.1)
 
23 881 (58.84)
4768 (11.78)
3773 (9.3)†
1046 (2.5)†
262 (0.6)
1225 (3.1)
5639 (13.9)
 
4605 (11.4)
9670 (24)
26 083 (64.6)
 
2971 (7.3)
16 976 (41.8)
20 411 (50.58)
 
18 755 (46.3)
6027 (14.9)
10 870 (26.8)
4868 (12)
 
10 559 (26)
2899 (7.16)
11 534 (28.4)
4446 (11)
324 (0.8)
10 764 (26.5)
68 (0.2)
28 106 (69.2)
 
8267 (20.4)
7272 (17.9)
661 (1.6)†
24 394 (60.1)
3117 (7.7)
1004 (2.5)
6537 (16.1)
22 513 (55.5)

61.57 (17.27)
8.87 (10.99)
66 741.3 (122 930.2)
39 764 (46.6)
 
6831 (8)
15 966 (18.7)
25 774 (30.2)†
36 749 (43.1)
21 435 (25.1)
 
47 357 (55.5)†
14 315 (16.8)
8145 (9.5)†
2020 (2.4)†
558 (0.7)
2054 (2.4)
10 871 (12.7)
 
11 170 (13.2)
21 958 (25.9)
51 720 (61)
 
9324 (10.9)
36 615 (42.9)
38 909 (45.6)
 
43 317 (50.9)
11 351 (13.3)
20 396 (24)
10 082 (11.8)
 
49 530 (58.1)
4062 (4.8)
15 086 (17.7)
10 590 (12.4)
1465 (1.7)
4518 (5.3)
69 (0.1)
61 034 (71.5)
 
14 560 (17.1)
16 877 (19.8)
1362 (1.6)†
52 521 (61.6)
3404 (4)
583 (0.7)
4738 (5.6)
0 (0)

<0.001
<0.001
<0.001
<0.001

Sepsis

19 764 (3.2)

20 584 (50.7)

14 173 (16.6)

<0.001

<0.001
<0.001
<0.001
<0.001
0.001
<0.001
<0.001
<0.001
<0.001
0.65
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
0.95
<0.001
<0.001
<0.001
<0.001
<0.001
Continued
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Continued
AP-NOF

AP-ARF

AP-OOF

N

n=624 617

n= 40594

n=85 320

Factor

N (%)

N (%)

N (%)

P value

Acute renal failure
Cardiogenic shock
Haematological dysfunction
Metabolic dysfunction
Hepatic dysfunction/acute liver failure
Smoking
Obesity
Congestive heart failure
Chronic pulmonary disease
Diabetes mellitus
Chronic renal failure
Chronic liver disease
Cancer
Drug abuse
Died
Mechanical ventilation

0 (0)
0 (0)
27 357 (4.4)
1643 (0.3)†
12 086 (1.9)
136 250 (21.8)
69 312 (11.1)†
29 578 (4.7)
84 760 (13.6)
142 173 (22.8)
36 723 (5.9)
57 242 (9.2)
12 756 (2)
30 499 (4.9)
3326 (0.5)
2892 (0.5)

22 937 (56.5)
4859 (12)
7909 (19.5)
69 (0.2)
5651 (13.9)
4952 (12.2)
4972 (12.2)
7608 (18.7)
8746 (21.5)
10 519 (25.9)
7319 (18.0)
4647 (11.4)
1484 (3.7)†
2114 (5.2)
10 764 (26.5)
26 813 (66.1)

73 881 (86.6)
18 037 (21.1)
9630 (11.3)
213 (0.2)†
4830 (5.7)
12 469 (14.6)
9662 (11.3)†
12 059 (24.5)
14 346 (16.8)
27 946 (32.8)
22 844 (26.8)
8928 (10.5)
3259 (3.8)†
3918 (4.6)
4518 (5.3)
3494 (4.1)

<0.001
<0.001
<0.001
0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
0.0025
<0.001
<0.001

The superscript † in the table between two cells denotes that those two values were not statistically significant. The p value stated would be for the other
values in that row.
*Missing variables (gender—0.1%; hospital bed—0.5%; primary payer—0.2%).
††The 29 Agency for Healthcare Research and Quality (AHRQ) comorbidity measures except alcohol abuse were used for risk adjustment based on the
methods by Elixhauser et al.29
AP-ARF, acute pancreatitis with acute respiratory failure; AP-NOF, acute pancreatitis with no organ failure; AP-OOF, acute pancreatitis with other organ
failure; ICF, intermediate care facility; SNF, skilled nursing facility.

the mortality rates decreased by 6.5% during the
same period of time. This trend is consistent with the
pattern of ARF in other conditions.22 30 The potential explanations for the reduction in mortality rates
include improvement in the management of the underlying aetiology and the ARF, with the increased use of
non-invasive ventilation, and advances in critical care
management.31 32
In our study, sepsis emerged as the top predictor
of ARF in patients with AP with an OR of 15 (95%
CI 14.7 to 15.4). Previous studies have shown that
sepsis is the most common cause of ARDS, accounting
for 25%–40% of the cases.33 Uncontrolled systemic
inflammatory response mediated by cytokines play a
critical role in the pathogenesis of ARDS.34 Alcohol
abuse and smoking are known risk factors for ARF in
AP.35 36 However, in our analysis, patients with smoking
Table 2

Organ failure in acute pancreatitis

Organ failure

N

None
624 617
Isolated organ failure
94 760
 Acute respiratory failure 16 038
 Isolated renal failure
67 283
 isolated cardiac failure
11 439
Multiple organ failure (2 or 31 154
more organs)

482

Per cent (95% CI)
83.22 (82.89 to 83.55)
12.63 (12.41 to 12.85)
2.13 (2.09 to 2.18)
8.97 (8.77 to 9.17)
1.52 (1.49 to 1.56)
4.15 (4.02 to 4.29)

history did not have a higher risk of ARF or mortality.
Although several studies have reported an association
between smoking and ARF,37–39 this association was
not replicated in some other studies.40 A recent meta-
analysis of 17 studies concluded that cigarette smoking
was not associated with an increased risk of ALI in critically ill patients.41 One plausible explanation could be
that the impact of smoking could be negligible when
compared with other precipitating factors. Also, there
is a potential for coding error or undercoding in the
database we used for the study.
Furthermore, diabetes mellitus was associated with
decreased risk of ARF and mortality in our study. This
finding is similar to a prospective multicentre study
in the USA, which showed that patients with diabetes
had a decreased incidence of ARDS and mortality in
patients with septic shock.42 The explanation for this
could be related to the impaired neutrophil function in
the diabetics, which may protect the lung by decreasing
the ability of the neutrophils to migrate into the lung
and their capacity to produce oxidant damage.42
The pathophysiology of the development of ARF
in AP involves increased pulmonary microvascular
permeability, which results in the spilling of protein-
rich transudate into the alveolar spaces that decreases
lung compliance. These are the hallmarks of ALI,
which manifest clinically as progressive hypoxaemia
with radiological evidence of diffuse infiltrates.43 Once

Gajendran M, et al. Frontline Gastroenterology 2021;12:478–486. doi:10.1136/flgastro-2020-101496

Pancreatobiliary
Table 3

Multivariate analysis for predictors of acute respiratory failure in patients with acute pancreatitis

Factor (s)

OR

95% CI

Gender: female
Age cat
 18–35
 36–50
 51–65
 >65
Hospital bed size
 Small (1–49)
 Moderate (50–99)
 Large (>100)
Teaching status
 Rural
 Urban, non-teaching
 Urban, teaching
Pancreatitis aetiology
 Biliary
 Alcohol
 Both alcohol and biliary
Pancreatic pseudocyst
Pneumonia
Pleural effusion
Sepsis
Cardiogenic shock
Smoking
Obesity
Congestive heart failure
Chronic pulmonary disease
Diabetes mellitus
Chronic renal failure
Chronic liver disease
Cancer
Drug abuse

0.78

0.76

0.80

<0.001

Reference
1.17
1.40
1.42

1.12
1.33
1.36

1.22
1.45
1.48

<0.001
<0.001
<0.001

Reference
1.15
1.39

1.11
1.34

1.19
1.44

<0.001
<0.001

Reference
1.61
1.98

1.55
1.90

1.68
2.06

<0.001
<0.001

Reference
2.34
1.61
1.20
3.79
4.03
15.04
3.24
0.67
1.29
2.23
1.52
0.89
1.22
1.06
1.01
1.27

2.24
1.47
1.15
3.45
3.88
14.68
3.11
0.65
1.24
2.16
1.48
0.86
1.18
1.02
0.95
1.20

2.43
1.77
1.26
4.17
4.18
15.41
3.37
0.69
1.37
2.31
1.57
0.91
1.26
1.10
1.07
1.33

<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
0.002
0.808
<0.001

the process of decrease in lung compliance and impairment of gas exchange becomes clinically evident, the
risk of progression to ARDS and, ultimately, multiple
organ dysfunction syndrome (MODS) increases.
Future research should focus on analysing the interplay between proinflammatory and anti-inflammatory
cytokines to prevent pulmonary involvement.
The AP-ARF group had a mortality rate of 26.5%,
and the presence of ARF alone increased the risk of
mortality by four times. Furthermore, 55% of patients
with ARF progressed to ARDS, and 66% required
mechanical ventilation. Previous population-
based
studies have reported a mortality rate ranging from
20% to 50% in patients admitted with ALI from all
causes.44 45 In patients with AP, ALI is a major component of the MODS, which frequently requires mechanical ventilation and a significant cause of early death
in severe AP.46 The mortality in MODS increases with
the number of involved organs.47 In our study, we have
reported that patients with MODS had a mortality rate

P value

of 28% when compared with 0.4% in those with no
OFs. In a study by Li et al, the presence of acute renal
failure in severe AP was associated with a significant
increase in hospital LOS, intensive care unit LOS, infection rate and mortality rate.48 In our study, the presence of ARF in AP increased the LOS by 8 days, and the
hospital charges by US$100 000. Similarly, in a prospective study of trauma patients, patients with ALI/ARDS
increased the cost by 30% and LOS by twofold.49
Some of the limitations in our study include coding
errors, lack of laboratory or medication data, and
possible unrecognised confounders associated with
administrative databases. A significant proportion of
patients in the AP-
ARF cohort also had congestive
cardiac failure and cardiogenic shock, which could
suggest that the primary pathophysiology among these
patients is pulmonary oedema from cardiac failure
rather than inflammation-mediated ARF. Owing to all
the above reasons, research using NIS data can never
substitute a prospective randomised clinical study.
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Table 4

Multivariate analysis for predictors of mortality in patients with acute respiratory failure and patients with acute pancreatitis

Factor (s)

HR

Gender: female
Age cat
 18–35
 36–50
 51–65
 >65
Hospital bed size
 Small (1–49)
 Moderate (50–99)
 Large (>100)
Teaching status
 Rural
 Urban, non-teaching
 Urban, teaching
Pancreatitis aetiology
 Biliary
 Alcohol
 Both alcohol and biliary
Pancreatic pseudocyst
Pleural effusion
Sepsis
Cardiogenic shock
Smoking
Obesity
Congestive heart failure
Chronic pulmonary disease
Diabetes mellitus
Chronic renal failure
Chronic liver disease
Cancer (not pancreatic cancer)
Drug abuse
Mechanical ventilation

0.947

0.914

0.980

0.002

Reference
1.508
2.342
5.031

1.390
2.168
4.663

1.635
2.529
5.428

<0.001
<0.001
<0.001

Reference
1.089
1.152

1.027
1.093

1.155
1.214

0.004
<0.001

Reference
0.989
1.103

0.934
1.041

1.048
1.168

0.706
0.001

Reference
2.243
1.293
0.622
0.946
5.064
2.467
0.666
0.769
1.378
1.030
0.750
1.536
1.681
2.801
0.853
14.221

2.101
1.098
0.572
0.890
4.872
2.338
0.627
0.722
1.315
0.985
0.720
1.470
1.593
2.616
0.775
13.664

2.394
1.523
0.677
1.006
5.263
2.603
0.708
0.819
1.444
1.076
0.781
1.605
1.773
2.999
0.939
14.800

<0.001
0.002
<0.001
0.076
<0.001
<0.001
<0.001
<0.001
<0.001
0.192
<0.001
<0.001
<0.001
<0.001
0.001
<0.001

In summary, concurrent ARF in hospitalised patients
with AP occurs at a perceptible prevalence with noticeable complications. This subgroup seems to have an
overall poor prognosis and more protracted clinical
course compared with patients with AP-OOF. These
results can be useful in allocating healthcare resources
and counselling patients.
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